Search
  • Site Search
  • News
  • Product

    • Zhejiang Medical Technology Development Co., Ltd.

    Winhealth Pharma Group helps make 12th Chinese Pharmacist Conference a complete success
    On October 16th, 2020, the 12th Chinese Pharmacist Conference, which was sponsored by the Chinese Pharmacists Association and the Expert Committee for Rational Drug Use of the National Health Commission of the People's Republic of China and was supported by Hongkong Winhealth Pharma Group Co., Ltd, was held in Beijing. Featuring the theme of 'Ability Creates Value', the conference discussed the pharmaceutical development and the pharmacist team construction from multiple perspectives. President Xi Jinping points out that health is an inevitable requirement for promoting people...
    Winhealth Pharma Group helps make 12th Chinese Pharmacist Conference a complete success
    Asahi Kasei and Winhealth Pharma Group reach strategic cooperation on Naftopidil®
    (October 12th, 2020, Hangzhou) Asahi Kasei Pharmaceutical Co., Ltd. (hereinafter referred to as 'Asahi Kasei') and Hongkong Winhealth Pharma Group Co., Ltd. (hereinafter referred to as 'Winhealth Pharma Group') held an online signing ceremony in Tokyo (Japan) and Hangzhou, announcing the strategic cooperation between the two parties: Asahi Kasei, as the license holder and manufacturer of its important product Naftopidil® (whose generic name is Naftopidil Tablets), granted the commercialization right of Naftopidil® in Mainland China to Winhealth Pharma G...
    Asahi Kasei and Winhealth Pharma Group reach strategic cooperation on Naftopidil®
    Winhealth Pharma Participated in the 2nd Healthy China Innovation Communication Conference ...
    Winhealth Pharma Participated in the 2nd Healthy China Innovation Communication Conference and the 7th China Medical Brand Building ConferenceFrom Sept. 25th to 26th, 2020, the 2nd Healthy China Innovation Communication Conference and the 7th China Medical Brand Building Conference, sponsored by the Chinese Medical Doctor Association, the Health Communication Working Committee of the Chinese Medical Doctor Association, the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration, and the Affiliated Hospital of Nantong University, was held in a grand way in Hai...
    Winhealth Pharma Participated in the 2nd Healthy China Innovation Communication Conference ...
    "Xenical" activates the life Launch meeting of Xenical® back to Chinese mainland ended successfully
    The heady fragrance of laurel blossoms wafts through the fresh air in the golden autumn. The launch meeting of Xenical® back to Chinese mainland was successfully held by Hong Kong Winhealth Pharma Group on Sept. 25. It means imported original Orlistat Capsules (brand name: Xenical®) return to the market of Chinese mainland officially.Several honored guests, including Mr. Wang Wei, president, founder and CEO of Hong Kong Winhealth Pharma Group, Prof. Zou Dajin, chief physician of Endocrinology Department of Shanghai Tenth People’s Hospital, Prof. Zhao Xiaolong, chief ph...
    "Xenical" activates the life Launch meeting of Xenical® back to Chinese mainland ended successfully
    Ferring and Winhealth reached strategic partnership of Glypressin®
    (July 7, 2020, Hangzhou) Ferring Pharmaceuticals and Hong Kong Winhealth Pharmaceutical Group Co., Ltd.  announced that they have reached a strategic partnership agreement. Ferring grants the commercial rights of its key product, Glypressin® (Terlipressin Acetate for Injection) to Winhealth for the distribution and promotion in mainland China. The partnership will come into effect on July 1, while Ferring remains as the license holder and manufacturer of the product. Glypressin® (Terlipressin Acetate for Injection), with the chemical name of triglyceride-8-lysine-vasopressi...
    Ferring and Winhealth reached strategic partnership of Glypressin®
    OVEREXPOSED — A Film About Light And Erythropoietic Protoporphyria
    OVEREXPOSED — A Film About Light And Erythropoietic Protoporphyria
    Winhealth Pharma and Clinuvel Signed Collaboration Agreement to Introduce SCENESSE® to China
    Hangzhou, China and Melbourne, Australia, 24 April 2020 HK Winhealth Pharma Group (hereafter referred to as “Winhealth Pharma”) and CLINUVEL signed a cooperation agreement on SCENESSE®, a new drug for treating the erythropoietic protoporphyria (EPP), indicating the first cooperation in the rare disease field.Through Winhealth Pharm and its subsidiaries, the Australian-based company CLINUVEL will launch SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for the treatment of the rare genetic metabolic disorder erythropoietic protoporphyria (EPP).1 ...
    Winhealth Pharma and Clinuvel Signed Collaboration Agreement to Introduce SCENESSE® to China
    3rd Floor, Winhealth Industrial Park, No. 272 Huancheng East Road, Xiacheng District, Hangzhou, Zhejiang, China
    BD@winhealth.Hk (overseas)
    0571-8718 6358    4008393773 ( Product Hotline ）
    Copyright ©2019 - 2024 Zhejiang Medical Technology Development Co., Ltd.
      网站地图
    浙ICP备12044547号
    Sitemap
    浙公网安备 33010302003458号